Scholtz & Company, LLC Cardiff Oncology, Inc. Transaction History

Scholtz & Company, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$5.18 - $7.24 $86,117 - $120,365	-16,625 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $83,291 - $126,017	16,625 New	16,625 $111,000
Q1 2021 May 17, 2021	SELL	$9.1 - $19.57 $328,737 - $706,966	-36,125 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$12.02 - $24.71 $8,414 - $17,297	-700 Reduced 1.9%	36,125 $650,000
Q3 2020 Nov 16, 2020	SELL	$4.25 - $14.19 $531 - $1,773	-125 Reduced 0.34%	36,825 $523,000
Q2 2020 Aug 14, 2020	BUY	$0.78 - $5.1 $28,821 - $188,445	36,950 New	36,950 $185,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $109M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Scholtz & Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Scholtz & Company, LLC with notifications on news.